<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/340288BD-BCA1-46AA-BA5C-D85DDA0D29C8"><gtr:id>340288BD-BCA1-46AA-BA5C-D85DDA0D29C8</gtr:id><gtr:name>August Pi i Sunyer Biomedical Research Institute (IDIBAPS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/872D8701-44D2-4D3C-B113-A795FA40D61F"><gtr:id>872D8701-44D2-4D3C-B113-A795FA40D61F</gtr:id><gtr:name>University of Helsinki</gtr:name><gtr:address><gtr:line1>Siltavuorenpenger 20 C</gtr:line1><gtr:line4>Helsinki</gtr:line4><gtr:line5>FI-00170</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/33952E5D-60ED-4D33-8638-669D9CFF6674"><gtr:id>33952E5D-60ED-4D33-8638-669D9CFF6674</gtr:id><gtr:name>Swiss Federal Institute of Technology (ETH), Zurich</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/789A99E8-D365-4EE7-89FB-F27ABF607526"><gtr:id>789A99E8-D365-4EE7-89FB-F27ABF607526</gtr:id><gtr:name>IntegraGen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9E00513E-B552-46CE-A64C-C0A5AB380DB0"><gtr:id>9E00513E-B552-46CE-A64C-C0A5AB380DB0</gtr:id><gtr:name>Jagiellonian University</gtr:name><gtr:address><gtr:line1>Golebia 24</gtr:line1><gtr:postCode>PL-31-007</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Poland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7756F85C-2731-467B-B256-18F2108A8914"><gtr:id>7756F85C-2731-467B-B256-18F2108A8914</gtr:id><gtr:name>Proteomika</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CE3FD7E0-3664-4B1E-9B3A-B30C8F846C6C"><gtr:id>CE3FD7E0-3664-4B1E-9B3A-B30C8F846C6C</gtr:id><gtr:name>Peninsula College Of Medecine and Dentistry Foundation</gtr:name><gtr:address><gtr:line1>Harscombe House 1 Darklake View
Estover</gtr:line1><gtr:city>Plymouth</gtr:city><gtr:postCode>PL6 7TL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4392299B-45A0-4B1F-A45B-28B39C51452F"><gtr:id>4392299B-45A0-4B1F-A45B-28B39C51452F</gtr:id><gtr:name>Broad Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FCD90BB9-BD1C-43D4-98EE-AE74283911E3"><gtr:id>FCD90BB9-BD1C-43D4-98EE-AE74283911E3</gtr:id><gtr:name>Free University of Brussels (ULB)</gtr:name><gtr:address><gtr:line1>Avenue Franklin Roosevelt 50</gtr:line1><gtr:postCode>B-1050</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED"><gtr:id>6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED</gtr:id><gtr:name>Technical University Dresden</gtr:name><gtr:address><gtr:line1>TU Dresden</gtr:line1><gtr:postCode>D-01062</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Unknown</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/340288BD-BCA1-46AA-BA5C-D85DDA0D29C8"><gtr:id>340288BD-BCA1-46AA-BA5C-D85DDA0D29C8</gtr:id><gtr:name>August Pi i Sunyer Biomedical Research Institute (IDIBAPS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/789A99E8-D365-4EE7-89FB-F27ABF607526"><gtr:id>789A99E8-D365-4EE7-89FB-F27ABF607526</gtr:id><gtr:name>IntegraGen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9E00513E-B552-46CE-A64C-C0A5AB380DB0"><gtr:id>9E00513E-B552-46CE-A64C-C0A5AB380DB0</gtr:id><gtr:name>Jagiellonian University</gtr:name><gtr:address><gtr:line1>Golebia 24</gtr:line1><gtr:postCode>PL-31-007</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Poland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7756F85C-2731-467B-B256-18F2108A8914"><gtr:id>7756F85C-2731-467B-B256-18F2108A8914</gtr:id><gtr:name>Proteomika</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4392299B-45A0-4B1F-A45B-28B39C51452F"><gtr:id>4392299B-45A0-4B1F-A45B-28B39C51452F</gtr:id><gtr:name>Broad Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED"><gtr:id>6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED</gtr:id><gtr:name>Technical University Dresden</gtr:name><gtr:address><gtr:line1>TU Dresden</gtr:line1><gtr:postCode>D-01062</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/872D8701-44D2-4D3C-B113-A795FA40D61F"><gtr:id>872D8701-44D2-4D3C-B113-A795FA40D61F</gtr:id><gtr:name>University of Helsinki</gtr:name><gtr:address><gtr:line1>Siltavuorenpenger 20 C</gtr:line1><gtr:line4>Helsinki</gtr:line4><gtr:line5>FI-00170</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/33952E5D-60ED-4D33-8638-669D9CFF6674"><gtr:id>33952E5D-60ED-4D33-8638-669D9CFF6674</gtr:id><gtr:name>Swiss Federal Institute of Technology (ETH), Zurich</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CE3FD7E0-3664-4B1E-9B3A-B30C8F846C6C"><gtr:id>CE3FD7E0-3664-4B1E-9B3A-B30C8F846C6C</gtr:id><gtr:name>Peninsula College Of Medecine and Dentistry Foundation</gtr:name><gtr:address><gtr:line1>Harscombe House 1 Darklake View
Estover</gtr:line1><gtr:city>Plymouth</gtr:city><gtr:postCode>PL6 7TL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FCD90BB9-BD1C-43D4-98EE-AE74283911E3"><gtr:id>FCD90BB9-BD1C-43D4-98EE-AE74283911E3</gtr:id><gtr:name>Free University of Brussels (ULB)</gtr:name><gtr:address><gtr:line1>Avenue Franklin Roosevelt 50</gtr:line1><gtr:postCode>B-1050</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1F16C5D5-2F34-42DB-9803-EF173B49584B"><gtr:id>1F16C5D5-2F34-42DB-9803-EF173B49584B</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:otherNames>L</gtr:otherNames><gtr:surname>Gloyn</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700222"><gtr:id>095107F2-51BC-4A8D-98BA-0EC36753953D</gtr:id><gtr:title>Insights into the regulation of glucokinase from novel mutational mechanisms causing pancreatic beta-cell dysfunction</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700222</gtr:grantReference><gtr:abstractText>Glucokinase plays an important role in insulin secretion and is a current therapeutic target for diabetes. Patients with faults in the gene encoding this protein can have either diabetes or raised fasting blood glucose that is usually treated by diet alone or low blood glucose levels which are usually treated with diazoxide. 

It is not understood how all of these faulty proteins result in low or high blood glucose values in patients. This study aims to investigate the mechanisms by which the defective genes cause diabetes or low blood glucose. Recently it has been discovered that some faults in genes do not cause disease because they change the protein; but that they affect the intermediate step of RNA processing that prevents or alters protein synthesis. My study will look at whether this is true for glucokinase gene defects. I will also look to see if some defects in genes cause disease because they prevent the glucokinase protein from being regulated by other proteins. This work is important because it will help interpret genetic test results and will also increase our understanding of an important drug target for the development of therapeutic agents to treat diabetes.</gtr:abstractText><gtr:technicalSummary>Glucokinase plays a central role in the regulation of insulin secretion. Variation within the glucokinase (GCK) gene is causally-related to a range of phenotypes reflecting beta-cell dysfunction including monogenic diabetes (MODY), hyperinsulinaemic hypoglycaemia (HI), glucose levels and birth weight. GCK activators represent an emerging therapeutic option for type 2 diabetes. 

The more than 200 GCK mutations so far implicated in monogenic conditions are widely-distributed across the gene. Molecular diagnostic testing is well-established in both MODY and HI, as identification of a GCK mutation provides information highly-relevant to the clinical management of the proband and their family. 

In addition to the clinical and physiological insights, the detailed functional analysis of GCK mutations has provided important clues into the function, structure and regulation of this key enzyme. To date, GCK mutations have been shown to display a range of mutational mechanisms including kinetic inactivation (causing MODY), activation (in HI) and thermal-lability. However, my own preliminary work has identified a number of clearly-pathogenic mutations for which routine kinetic studies have failed to demonstrate a molecular basis for pathogenicity, or where kinetic studies may actually be misleading. I have also identified and characterised a large number of families segregating GCK-like MODY in whom extensive resequencing has failed to identify GCK mutations; and HI cases in whom all known genetic causes have been excluded. 

A range of mutational mechanisms may be operating in these individuals: including abnormalities of RNA processing, disruptions of the interactions between GCK and regulatory/binding partners, copy number variation (CNV), and/or mutations in genes encoding regulatory partners of GCK. A detailed understanding of the molecular mechanisms involved will not only add novel clues to the regulation and function of GCK: it is also critical for appropriate clinical management.

The aims of this project are: 
(i) to perform a systematic assessment of a selected group of 34 GCK-MODY mutations to identify the mutational mechanisms responsible: this will involve studies of mRNA processing, enzyme kinetics, interaction dynamics and mRNA and protein stability. 
(ii) to determine the role of CNV in GCK-related phenotypes;
(iii) to investigate the role of mutations in the gene(s) encoding important islet GCK- regulatory proteins in beta-cell dysfunction.

This work should provide: (i) improved clinical diagnostics for families with monogenic diabetes and HI; (ii) insights into fundamental mechanisms of beta-cell regulation and function (relevant to all forms of diabetes); and (iii) the potential for novel, improved therapeutic tools for manipulation of beta-cell function.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>350389</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Functional studies on genetic variants of glucokinase regulatory protein</gtr:description><gtr:id>44546A46-C33C-46DC-B1A3-18F281E57076</gtr:id><gtr:impact>Funding from NIH for Matthew Rees' 4 year PhD studentship. 19643913</gtr:impact><gtr:outcomeId>44F0D050516-1</gtr:outcomeId><gtr:partnerContribution>Dr Marju Orho-Melander was involved in the identification of the P446L GCKR variant and its role in blood glucose levels in the general population. Dr Orho-Melander provided genetic information for my functional studies. Professor David Altshuler and his team at the Broad were involved in the discovery that a common genetic variant in glucokinase regulatory protein (P446L) was involved in fasting plasma glucose levels in the general population. This information was shared with me prior to publication. I have a collaboration with Francis Collins. We now have a joint PhD student (Matthew Rees) who is funded on the NIH/Oxbridge system. Matt is spending half of his time in my laboratory working on the kinetic characterisation of rare genetics variants identified in patients with abnormal glucose and lipid levels and the remaining time at NIH working on the cellular characterisation of these variants. The majority of these rare variants have been identified in the NIH Clin Seq project. My MRC funded PhD student (Nicola Beer) has visited NIH for a 3 month visit funded by the European Foundation for the Study of Diabetes (EFSD) to perform some cellular studies on the P446L glucokinase regulatory protein variant protein.</gtr:partnerContribution><gtr:piContribution>I have set up a research collaboration on glucokinase regulatory protein with Dr Francis Collins (NIH, Bethesda, USA), Dr Marjo Orho-Melander (Lund University, Sweden) and Dr David Altshuler (Broad Institute of Harvard and MIT, Boston, USA). This collaboration now involves a joint student (Matthew Rees) with Prof Francis Collins (NIH) who is funded by the NIH/Oxbridge system. Matt is spending half his time in my laboratory working on the kinetic characterisation of rare genetic variants in glucokinase regulatory protein GCKR). Matt is working closely with my MRC funded PhD student Nicola Beer who also works on glucokinase regulatory protein (Beer et al Human Molecular Genetics 2009; 19643913 ). My lab has hosted a PhD student (Charlotta Roos) from Dr Orho-Melander's group for a 3 month visit to work on GKRP. This was funded by an European Foundation for the Study of Diabetes (EFSD) travelling fellowship.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technical University of Dresden</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>CEED3 (Collaborative European Effort to Develop Diabetes Diagnostics)</gtr:description><gtr:id>0C360D4D-906F-4B97-8DE6-1C509402B9B5</gtr:id><gtr:impact>My senior author paper published in Diabetes Care (PubMed 20724646) partly resulted through this initative. This study has shown for the first time that CRP is a potential biomarker which can be used to prioritise patients for genetic testing for HNF1A-MODY.
This is a mutli-disciplinary collaboration with basic scientists, clinicians.</gtr:impact><gtr:outcomeId>3C0BF01790A-10</gtr:outcomeId><gtr:partnerContribution>This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage.</gtr:partnerContribution><gtr:piContribution>I am involved in the Biomarker discovery for monogenic diabetes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Proteomika</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>CEED3 (Collaborative European Effort to Develop Diabetes Diagnostics)</gtr:description><gtr:id>937215ED-E4F2-4E85-B91D-BD0716E32B5D</gtr:id><gtr:impact>My senior author paper published in Diabetes Care (PubMed 20724646) partly resulted through this initative. This study has shown for the first time that CRP is a potential biomarker which can be used to prioritise patients for genetic testing for HNF1A-MODY.
This is a mutli-disciplinary collaboration with basic scientists, clinicians.</gtr:impact><gtr:outcomeId>3C0BF01790A-8</gtr:outcomeId><gtr:partnerContribution>This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage.</gtr:partnerContribution><gtr:piContribution>I am involved in the Biomarker discovery for monogenic diabetes.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>CEED3 (Collaborative European Effort to Develop Diabetes Diagnostics)</gtr:description><gtr:id>3CC26EF8-1524-4205-B00B-EC0D63C95F04</gtr:id><gtr:impact>My senior author paper published in Diabetes Care (PubMed 20724646) partly resulted through this initative. This study has shown for the first time that CRP is a potential biomarker which can be used to prioritise patients for genetic testing for HNF1A-MODY.
This is a mutli-disciplinary collaboration with basic scientists, clinicians.</gtr:impact><gtr:outcomeId>3C0BF01790A-3</gtr:outcomeId><gtr:partnerContribution>This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage.</gtr:partnerContribution><gtr:piContribution>I am involved in the Biomarker discovery for monogenic diabetes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>National Human Genome Research Institute (NHGRI)</gtr:department><gtr:description>Functional studies on genetic variants of glucokinase regulatory protein</gtr:description><gtr:id>7FB857BC-59C8-4C5D-8335-F0020D63199E</gtr:id><gtr:impact>Funding from NIH for Matthew Rees' 4 year PhD studentship. 19643913</gtr:impact><gtr:outcomeId>44F0D050516-3</gtr:outcomeId><gtr:partnerContribution>Dr Marju Orho-Melander was involved in the identification of the P446L GCKR variant and its role in blood glucose levels in the general population. Dr Orho-Melander provided genetic information for my functional studies. Professor David Altshuler and his team at the Broad were involved in the discovery that a common genetic variant in glucokinase regulatory protein (P446L) was involved in fasting plasma glucose levels in the general population. This information was shared with me prior to publication. I have a collaboration with Francis Collins. We now have a joint PhD student (Matthew Rees) who is funded on the NIH/Oxbridge system. Matt is spending half of his time in my laboratory working on the kinetic characterisation of rare genetics variants identified in patients with abnormal glucose and lipid levels and the remaining time at NIH working on the cellular characterisation of these variants. The majority of these rare variants have been identified in the NIH Clin Seq project. My MRC funded PhD student (Nicola Beer) has visited NIH for a 3 month visit funded by the European Foundation for the Study of Diabetes (EFSD) to perform some cellular studies on the P446L glucokinase regulatory protein variant protein.</gtr:partnerContribution><gtr:piContribution>I have set up a research collaboration on glucokinase regulatory protein with Dr Francis Collins (NIH, Bethesda, USA), Dr Marjo Orho-Melander (Lund University, Sweden) and Dr David Altshuler (Broad Institute of Harvard and MIT, Boston, USA). This collaboration now involves a joint student (Matthew Rees) with Prof Francis Collins (NIH) who is funded by the NIH/Oxbridge system. Matt is spending half his time in my laboratory working on the kinetic characterisation of rare genetic variants in glucokinase regulatory protein GCKR). Matt is working closely with my MRC funded PhD student Nicola Beer who also works on glucokinase regulatory protein (Beer et al Human Molecular Genetics 2009; 19643913 ). My lab has hosted a PhD student (Charlotta Roos) from Dr Orho-Melander's group for a 3 month visit to work on GKRP. This was funded by an European Foundation for the Study of Diabetes (EFSD) travelling fellowship.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Helsinki</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>CEED3 (Collaborative European Effort to Develop Diabetes Diagnostics)</gtr:description><gtr:id>A22FA2C9-5ED4-49AA-BEA4-2130550E5055</gtr:id><gtr:impact>My senior author paper published in Diabetes Care (PubMed 20724646) partly resulted through this initative. This study has shown for the first time that CRP is a potential biomarker which can be used to prioritise patients for genetic testing for HNF1A-MODY.
This is a mutli-disciplinary collaboration with basic scientists, clinicians.</gtr:impact><gtr:outcomeId>3C0BF01790A-9</gtr:outcomeId><gtr:partnerContribution>This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage.</gtr:partnerContribution><gtr:piContribution>I am involved in the Biomarker discovery for monogenic diabetes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ETH Zurich</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Institute of Molecular Systems Biology</gtr:department><gtr:description>CEED3 (Collaborative European Effort to Develop Diabetes Diagnostics)</gtr:description><gtr:id>4514834D-F6B4-4BF9-A80B-6639BE926C14</gtr:id><gtr:impact>My senior author paper published in Diabetes Care (PubMed 20724646) partly resulted through this initative. This study has shown for the first time that CRP is a potential biomarker which can be used to prioritise patients for genetic testing for HNF1A-MODY.
This is a mutli-disciplinary collaboration with basic scientists, clinicians.</gtr:impact><gtr:outcomeId>3C0BF01790A-7</gtr:outcomeId><gtr:partnerContribution>This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage.</gtr:partnerContribution><gtr:piContribution>I am involved in the Biomarker discovery for monogenic diabetes.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>August Pi i Sunyer Biomedical Research Institute (IDIBAPS)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>Hospital Clinic of Barcelona</gtr:department><gtr:description>CEED3 (Collaborative European Effort to Develop Diabetes Diagnostics)</gtr:description><gtr:id>A5542B7B-81AD-4DC0-AE9C-3840AEDB8CA3</gtr:id><gtr:impact>My senior author paper published in Diabetes Care (PubMed 20724646) partly resulted through this initative. This study has shown for the first time that CRP is a potential biomarker which can be used to prioritise patients for genetic testing for HNF1A-MODY.
This is a mutli-disciplinary collaboration with basic scientists, clinicians.</gtr:impact><gtr:outcomeId>3C0BF01790A-5</gtr:outcomeId><gtr:partnerContribution>This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage.</gtr:partnerContribution><gtr:piContribution>I am involved in the Biomarker discovery for monogenic diabetes.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Free University of Brussels</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>CEED3 (Collaborative European Effort to Develop Diabetes Diagnostics)</gtr:description><gtr:id>C99E0B0B-D50E-42B3-9CA3-DD6A78374315</gtr:id><gtr:impact>My senior author paper published in Diabetes Care (PubMed 20724646) partly resulted through this initative. This study has shown for the first time that CRP is a potential biomarker which can be used to prioritise patients for genetic testing for HNF1A-MODY.
This is a mutli-disciplinary collaboration with basic scientists, clinicians.</gtr:impact><gtr:outcomeId>3C0BF01790A-6</gtr:outcomeId><gtr:partnerContribution>This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage.</gtr:partnerContribution><gtr:piContribution>I am involved in the Biomarker discovery for monogenic diabetes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Broad Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Functional studies on genetic variants of glucokinase regulatory protein</gtr:description><gtr:id>483B072D-C9CC-4014-9262-55E6DA2F6B2F</gtr:id><gtr:impact>Funding from NIH for Matthew Rees' 4 year PhD studentship. 19643913</gtr:impact><gtr:outcomeId>44F0D050516-2</gtr:outcomeId><gtr:partnerContribution>Dr Marju Orho-Melander was involved in the identification of the P446L GCKR variant and its role in blood glucose levels in the general population. Dr Orho-Melander provided genetic information for my functional studies. Professor David Altshuler and his team at the Broad were involved in the discovery that a common genetic variant in glucokinase regulatory protein (P446L) was involved in fasting plasma glucose levels in the general population. This information was shared with me prior to publication. I have a collaboration with Francis Collins. We now have a joint PhD student (Matthew Rees) who is funded on the NIH/Oxbridge system. Matt is spending half of his time in my laboratory working on the kinetic characterisation of rare genetics variants identified in patients with abnormal glucose and lipid levels and the remaining time at NIH working on the cellular characterisation of these variants. The majority of these rare variants have been identified in the NIH Clin Seq project. My MRC funded PhD student (Nicola Beer) has visited NIH for a 3 month visit funded by the European Foundation for the Study of Diabetes (EFSD) to perform some cellular studies on the P446L glucokinase regulatory protein variant protein.</gtr:partnerContribution><gtr:piContribution>I have set up a research collaboration on glucokinase regulatory protein with Dr Francis Collins (NIH, Bethesda, USA), Dr Marjo Orho-Melander (Lund University, Sweden) and Dr David Altshuler (Broad Institute of Harvard and MIT, Boston, USA). This collaboration now involves a joint student (Matthew Rees) with Prof Francis Collins (NIH) who is funded by the NIH/Oxbridge system. Matt is spending half his time in my laboratory working on the kinetic characterisation of rare genetic variants in glucokinase regulatory protein GCKR). Matt is working closely with my MRC funded PhD student Nicola Beer who also works on glucokinase regulatory protein (Beer et al Human Molecular Genetics 2009; 19643913 ). My lab has hosted a PhD student (Charlotta Roos) from Dr Orho-Melander's group for a 3 month visit to work on GKRP. This was funded by an European Foundation for the Study of Diabetes (EFSD) travelling fellowship.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Jagiellonian University</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:description>CEED3 (Collaborative European Effort to Develop Diabetes Diagnostics)</gtr:description><gtr:id>83BCDAD9-0684-4409-AC16-818FD2F9CD97</gtr:id><gtr:impact>My senior author paper published in Diabetes Care (PubMed 20724646) partly resulted through this initative. This study has shown for the first time that CRP is a potential biomarker which can be used to prioritise patients for genetic testing for HNF1A-MODY.
This is a mutli-disciplinary collaboration with basic scientists, clinicians.</gtr:impact><gtr:outcomeId>3C0BF01790A-4</gtr:outcomeId><gtr:partnerContribution>This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage.</gtr:partnerContribution><gtr:piContribution>I am involved in the Biomarker discovery for monogenic diabetes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>IntegraGen</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>CEED3 (Collaborative European Effort to Develop Diabetes Diagnostics)</gtr:description><gtr:id>6C44106B-5EE8-45E0-B16D-B7769839078A</gtr:id><gtr:impact>My senior author paper published in Diabetes Care (PubMed 20724646) partly resulted through this initative. This study has shown for the first time that CRP is a potential biomarker which can be used to prioritise patients for genetic testing for HNF1A-MODY.
This is a mutli-disciplinary collaboration with basic scientists, clinicians.</gtr:impact><gtr:outcomeId>3C0BF01790A-2</gtr:outcomeId><gtr:partnerContribution>This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage.</gtr:partnerContribution><gtr:piContribution>I am involved in the Biomarker discovery for monogenic diabetes.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Peninsula College of Medicine &amp; Dentistry</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CEED3 (Collaborative European Effort to Develop Diabetes Diagnostics)</gtr:description><gtr:id>14DBD3B8-F2D5-4F9F-AE8B-823D60671089</gtr:id><gtr:impact>My senior author paper published in Diabetes Care (PubMed 20724646) partly resulted through this initative. This study has shown for the first time that CRP is a potential biomarker which can be used to prioritise patients for genetic testing for HNF1A-MODY.
This is a mutli-disciplinary collaboration with basic scientists, clinicians.</gtr:impact><gtr:outcomeId>3C0BF01790A-1</gtr:outcomeId><gtr:partnerContribution>This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage. This grant has only been running for one month so hard to assess the contributions at this stage.</gtr:partnerContribution><gtr:piContribution>I am involved in the Biomarker discovery for monogenic diabetes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Diabetes UK Voluntary Group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>F68A0DDB-EA3B-4108-9B48-AC510A099810</gtr:id><gtr:impact>Approximately 30 patients with diabetes and their relatives attended a talk giving an overview of research in my group. The talk was well received and generated substantial interest in our research activities.

No measurable impact reported to date.</gtr:impact><gtr:outcomeId>tcgomkJPQBq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>72000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Diabetes UK Studentship</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:id>293F3CA8-1DEA-4199-9E86-344BBDC17F00</gtr:id><gtr:outcomeId>YKDZCorxXS40</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>212076</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Training Fellowship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F6CE2D61-9DFA-4029-A8D8-9BF666A55876</gtr:id><gtr:outcomeId>1DDA6FBA5780</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>124571</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Diabetes UK, Clinical Training Fellowship</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:id>03D40DDB-5D59-48F5-B6AC-564AFC55C6B8</gtr:id><gtr:outcomeId>A91C64AA6ED0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Senior Fellowship in Basic Biomedical Research</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>896B0E1C-748D-49B7-B0E1-A8285136F4C4</gtr:id><gtr:outcomeId>ePyzU82nQSx0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have published a mutation update (Osbak et al Human Mutation 2009) which details &amp;gt;600 naturally occurring glucokinase mutations which cause human disease. In addition to the database of mutations a comprehensive list of non-pathogenic genetic variation has also been compiled.</gtr:description><gtr:id>D28573C8-9692-4C46-A88C-5B7AC51367BD</gtr:id><gtr:impact>This database of mutations provides an important tool for laboratories offering genetic diagnostic testing for glucokinase glycaemic disorders.</gtr:impact><gtr:outcomeId>733893AAB56</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Glucokinase mutation update</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>05C71F2D-28B5-47A0-8EC7-0447674E16DD</gtr:id><gtr:title>New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/695b1fb9d910198e8ecc013960e72c2f"><gtr:id>695b1fb9d910198e8ecc013960e72c2f</gtr:id><gtr:otherNames>Dupuis J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>nFASB6dcwx6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6578ED4-9399-4DDC-B066-8F1442305D99</gtr:id><gtr:title>Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bbac37c4f86588c8e289e41409751c3"><gtr:id>2bbac37c4f86588c8e289e41409751c3</gtr:id><gtr:otherNames>Strawbridge RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>Jvm49rmzUUB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2622DB80-A5AA-4E8E-85A5-94A90721CE83</gtr:id><gtr:title>From genetic association to molecular mechanism.</gtr:title><gtr:parentPublicationTitle>Current diabetes reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec988b3a67ed2845ca470b8b54f847d7"><gtr:id>ec988b3a67ed2845ca470b8b54f847d7</gtr:id><gtr:otherNames>van de Bunt M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1534-4827</gtr:issn><gtr:outcomeId>hxz9RrQXwVM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB6AFF14-1A84-4E2A-AEC9-C905E67403C8</gtr:id><gtr:title>Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b7d6b34c2d3d9a0b559f7ca9d878efb"><gtr:id>5b7d6b34c2d3d9a0b559f7ca9d878efb</gtr:id><gtr:otherNames>Rees MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>Y3huC9iFgmv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>934A8AD4-17D6-46C5-9ED1-A5770EBD5DDD</gtr:id><gtr:title>Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a32bbd11c23d7a64aed2c75a9fcbe74"><gtr:id>8a32bbd11c23d7a64aed2c75a9fcbe74</gtr:id><gtr:otherNames>Herrera BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>Bg2cAzr7ioF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FEE31DB-8244-400A-8A1B-CA5078EE93CC</gtr:id><gtr:title>Species-specific differences in the expression of the HNF1A, HNF1B and HNF4A genes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/325d6855f82e5b364cfe4aeb260441af"><gtr:id>325d6855f82e5b364cfe4aeb260441af</gtr:id><gtr:otherNames>Harries LW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>ABB3741B43D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A144BFD-7B9D-414A-9F53-BB65B18055BF</gtr:id><gtr:title>Naturally occurring glucokinase mutations are associated with defects in posttranslational S-nitrosylation.</gtr:title><gtr:parentPublicationTitle>Molecular endocrinology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81474c055aec694542da241358039632"><gtr:id>81474c055aec694542da241358039632</gtr:id><gtr:otherNames>Ding SY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0888-8809</gtr:issn><gtr:outcomeId>E9C7C215ADF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A17C9C10-1704-4628-A32D-B93078198DEA</gtr:id><gtr:title>Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fd3cc7d5807a18dec29f22b0fc45336"><gtr:id>6fd3cc7d5807a18dec29f22b0fc45336</gtr:id><gtr:otherNames>Voight BF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>KUe4s4eZfMv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F939786E-C8A2-48FA-BA6C-2735F1387CF6</gtr:id><gtr:title>RD Lawrence Lecture 2009. Old genes, new tricks: learning about blood glucose regulation from naturally occurring genetic variation in humans.</gtr:title><gtr:parentPublicationTitle>Diabetic medicine : a journal of the British Diabetic Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdad400bea3e692bc69056f0cf339d5d"><gtr:id>bdad400bea3e692bc69056f0cf339d5d</gtr:id><gtr:otherNames>Gloyn AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0742-3071</gtr:issn><gtr:outcomeId>4CB4806082B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E058E58-77D9-4B81-B61D-3EBD82A87012</gtr:id><gtr:title>A role for coding functional variants in HNF4A in type 2 diabetes susceptibility.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/575fc3f8e9fb59364256f12a5bea1c28"><gtr:id>575fc3f8e9fb59364256f12a5bea1c28</gtr:id><gtr:otherNames>Jafar-Mohammadi B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>oVXEa8s6PoA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A765CED0-3773-45E7-A8D4-9C4A3B13CB93</gtr:id><gtr:title>Glucokinase (GCK) and other susceptibility genes for beta-cell dysfunction: the candidate approach.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdad400bea3e692bc69056f0cf339d5d"><gtr:id>bdad400bea3e692bc69056f0cf339d5d</gtr:id><gtr:otherNames>Gloyn AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>1D5F21CE931</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6CB35EF-823A-48D7-82B9-2143BF797924</gtr:id><gtr:title>Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e78bca6a55c97f7270f0225c4ce95989"><gtr:id>e78bca6a55c97f7270f0225c4ce95989</gtr:id><gtr:otherNames>Osbak KK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>D1E0CFAB6D3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3D1F811-6B8E-4CE9-9E65-2584FF1855D4</gtr:id><gtr:title>GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: implications for understanding genetic association signals at this locus.</gtr:title><gtr:parentPublicationTitle>Molecular genetics and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29bcec116f3d60bde341065a48284c10"><gtr:id>29bcec116f3d60bde341065a48284c10</gtr:id><gtr:otherNames>McCulloch LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1096-7192</gtr:issn><gtr:outcomeId>iMg7UcVyBhn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EF90EFD-F37D-4887-9D4A-4A709F37ACEC</gtr:id><gtr:title>Gene duplications resulting in over expression of glucokinase are not a common cause of hypoglycaemia of infancy in humans.</gtr:title><gtr:parentPublicationTitle>Molecular genetics and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec988b3a67ed2845ca470b8b54f847d7"><gtr:id>ec988b3a67ed2845ca470b8b54f847d7</gtr:id><gtr:otherNames>van de Bunt M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1096-7192</gtr:issn><gtr:outcomeId>507A3A72029</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE54D6E1-4E90-4B7C-A16D-1A4DC5976725</gtr:id><gtr:title>Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/101bf38360eae3bf04c62daac91464b2"><gtr:id>101bf38360eae3bf04c62daac91464b2</gtr:id><gtr:otherNames>Flanagan SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>pm_12547_17_18767144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F80CB2F-8E24-4A17-A211-37C1C13FD09F</gtr:id><gtr:title>Comprehensive human adipose tissue mRNA and microRNA endogenous control selection for quantitative real-time-PCR normalization.</gtr:title><gtr:parentPublicationTitle>Obesity (Silver Spring, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a30167a9a34d5ade5f5e76416c5387eb"><gtr:id>a30167a9a34d5ade5f5e76416c5387eb</gtr:id><gtr:otherNames>Neville MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1930-7381</gtr:issn><gtr:outcomeId>qTiqh79PC4K</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5ADE373E-A491-4C70-86C1-9ACEF4BE36CB</gtr:id><gtr:title>The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fade1b52b6fb14dfe42965f695ae499"><gtr:id>0fade1b52b6fb14dfe42965f695ae499</gtr:id><gtr:otherNames>Beer NL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>FB0BBC2122B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CFAF218-583A-4C18-BF2E-6AE9660205AA</gtr:id><gtr:title>Low frequency variants in the exons only encoding isoform A of HNF1A do not contribute to susceptibility to type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/575fc3f8e9fb59364256f12a5bea1c28"><gtr:id>575fc3f8e9fb59364256f12a5bea1c28</gtr:id><gtr:otherNames>Jafar-Mohammadi B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>A2E2619189D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54287992-8443-425F-9804-C21780679B9C</gtr:id><gtr:title>The previously reported T342P GCK missense variant is not a pathogenic mutation causing MODY.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d54e2c0164cc193ed2e7086126694f4"><gtr:id>8d54e2c0164cc193ed2e7086126694f4</gtr:id><gtr:otherNames>Steele AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>pb86TtuB1kb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB67B845-9850-438A-B72E-6F2D2A853829</gtr:id><gtr:title>Insights into the pathogenicity of rare missense GCK variants from the identification and functional characterization of compound heterozygous and double mutations inherited in cis.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fade1b52b6fb14dfe42965f695ae499"><gtr:id>0fade1b52b6fb14dfe42965f695ae499</gtr:id><gtr:otherNames>Beer NL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>pm_12547_27_22611063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08400D2D-B212-4C09-BA9D-A27BF9450A2A</gtr:id><gtr:title>Variation across the allele frequency spectrum.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdad400bea3e692bc69056f0cf339d5d"><gtr:id>bdad400bea3e692bc69056f0cf339d5d</gtr:id><gtr:otherNames>Gloyn AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>Bmjix9uhUaL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E277E6B1-DE62-4014-B27E-CEE4860F60AC</gtr:id><gtr:title>Prevalence of GCK mutations in individuals screened for fasting hyperglycaemia.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdad400bea3e692bc69056f0cf339d5d"><gtr:id>bdad400bea3e692bc69056f0cf339d5d</gtr:id><gtr:otherNames>Gloyn AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>pm_12547_17_19002431</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D55A0ED-8083-438D-B8BA-D27F8958DC90</gtr:id><gtr:title>Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71021eeab8a447bb5bcf837207b96627"><gtr:id>71021eeab8a447bb5bcf837207b96627</gtr:id><gtr:otherNames>Owen KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>LR2n1L3J6t3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B69B6389-148B-4264-B46A-2EC9B31FC1C2</gtr:id><gtr:title>A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bddf78ecec8371852d62ce67ec3131cc"><gtr:id>bddf78ecec8371852d62ce67ec3131cc</gtr:id><gtr:otherNames>Thanabalasingham G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>no8TCq8nGeh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F2B90C1-1B85-479A-968F-ED5A290FBA09</gtr:id><gtr:title>Mutations in the third gene shown to alter fasting glucose levels in the population (G6PC2) are not a common cause of monogenic forms of pancreatic B-cell dysfunction.</gtr:title><gtr:parentPublicationTitle>Diabetic medicine : a journal of the British Diabetic Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/957cb691da509734634ed68223c7780d"><gtr:id>957cb691da509734634ed68223c7780d</gtr:id><gtr:otherNames>Edghill EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0742-3071</gtr:issn><gtr:outcomeId>DE9F2032F83</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BB271F0-1D94-4C44-9173-0D51F5D70D79</gtr:id><gtr:title>Discovery of a novel site regulating glucokinase activity following characterization of a new mutation causing hyperinsulinemic hypoglycemia in humans.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fade1b52b6fb14dfe42965f695ae499"><gtr:id>0fade1b52b6fb14dfe42965f695ae499</gtr:id><gtr:otherNames>Beer NL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>HF1ark6ZQfv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B82A5547-0F9E-449E-8A91-1A3288109EFB</gtr:id><gtr:title>Type 2 diabetes susceptibility gene TCF7L2 and its role in beta-cell function.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdad400bea3e692bc69056f0cf339d5d"><gtr:id>bdad400bea3e692bc69056f0cf339d5d</gtr:id><gtr:otherNames>Gloyn AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>CF13145F4C6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8321A62-E54B-48AD-8C9C-B56E3A73A320</gtr:id><gtr:title>Metabolic profiling in Maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdad400bea3e692bc69056f0cf339d5d"><gtr:id>bdad400bea3e692bc69056f0cf339d5d</gtr:id><gtr:otherNames>Gloyn AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12547_27_22859960</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7D8813B-1EB2-422C-B9E0-25461DADC638</gtr:id><gtr:title>PTEN mutations as a cause of constitutive insulin sensitivity and obesity.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5b0014925c78d1f72d48bc09ae442a2"><gtr:id>b5b0014925c78d1f72d48bc09ae442a2</gtr:id><gtr:otherNames>Pal A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_12547_27_22970944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0411F332-CA8F-4F66-B4A1-67B6B9C989EA</gtr:id><gtr:title>Identification of a novel beta-cell glucokinase (GCK) promoter mutation (-71G&amp;gt;C) that modulates GCK gene expression through loss of allele-specific Sp1 binding causing mild fasting hyperglycemia in humans.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bcc6dc47e9c27cedf4e399008b7455a"><gtr:id>2bcc6dc47e9c27cedf4e399008b7455a</gtr:id><gtr:otherNames>Gasper?kov? D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>E341A6C54A4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99429E1F-CBAD-4F71-80C4-781DCB1E3EF0</gtr:id><gtr:title>Genetics: how the UKPDS contributed to determining the genetic landscape of Type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetic medicine : a journal of the British Diabetic Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdad400bea3e692bc69056f0cf339d5d"><gtr:id>bdad400bea3e692bc69056f0cf339d5d</gtr:id><gtr:otherNames>Gloyn AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0742-3071</gtr:issn><gtr:outcomeId>23C50AADEA2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B407FA2-2517-4F64-8A30-529BC6FDFBB1</gtr:id><gtr:title>High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4b88d18de15b259f8f585a3131ccc35"><gtr:id>a4b88d18de15b259f8f585a3131ccc35</gtr:id><gtr:otherNames>McDonald TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>ZEu9QxdBeTD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAB022F7-4AD8-47ED-995C-34DF74C34522</gtr:id><gtr:title>Identification and functional characterisation of novel glucokinase mutations causing maturity-onset diabetes of the young in Slovakia.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/524f9d543ad80809f360514ad79e8457"><gtr:id>524f9d543ad80809f360514ad79e8457</gtr:id><gtr:otherNames>Valent?nov? L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12547_27_22493702</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D50D976-2473-4FC5-95F3-0CDB2C7EDD63</gtr:id><gtr:title>Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5b0014925c78d1f72d48bc09ae442a2"><gtr:id>b5b0014925c78d1f72d48bc09ae442a2</gtr:id><gtr:otherNames>Pal A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>9F2A1B93180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0207D4C3-8FE0-46FB-A643-E023CD99313C</gtr:id><gtr:title>Correlation of rare coding variants in the gene encoding human glucokinase regulatory protein with phenotypic, cellular, and kinetic outcomes.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b7d6b34c2d3d9a0b559f7ca9d878efb"><gtr:id>5b7d6b34c2d3d9a0b559f7ca9d878efb</gtr:id><gtr:otherNames>Rees MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>eeApHepwHg8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEC0C431-3766-43FC-A7BF-0E3C3F6306F2</gtr:id><gtr:title>Severe insulin resistance and intrauterine growth deficiency associated with haploinsufficiency for INSR and CHN2: new insights into synergistic pathways involved in growth and metabolism.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acdc1dc7b6dc5824585de6f2739ed52f"><gtr:id>acdc1dc7b6dc5824585de6f2739ed52f</gtr:id><gtr:otherNames>Suliman SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>541BEC4F788</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2164331D-7C11-4BC2-AF9A-5C20FA194E61</gtr:id><gtr:title>Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f522534260429e9c59647259e167ded"><gtr:id>4f522534260429e9c59647259e167ded</gtr:id><gtr:otherNames>Hamming KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>DA7A5A7BED9</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700222</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>